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Background
MGN1703, a potent immunomodulatory Toll-like recep-
tor 9 (TLR-9) agonist, was compared to placebo in the
previous double-blind, randomized Phase II IMPACT
study. The drug was given as switch maintenance in 59
patients with metastatic colorectal cancer (mCRC)
not progressing after 4.5 to 6 months of induction che-
motherapy +/- bevacizumab, considered the most appro-
priate setting for an agent broadly activating the immune
system. MGN1703 showed a superior effect over placebo,
with a hazard ratio (HR) for the primary endpoint “PFS on
maintenance” of 0.55 (p=0.041) by local assessment.
Exploratory PFS analyses of pretreatment characteristics
identified patients with objective RECIST response, nor-
malized CEA and presence of activated NKT cells at the
end of induction treatment to benefit the most with
MGN1703 maintenance. Furthermore, the subgroup of
patients with RECIST response after induction therapy
reported a HR of 0.40 (median 24.5 vs. 15.1 months) for
overall survival (OS). These results warranted confirma-
tion in a larger Phase III study.
Methods
The IMPALA study (NCT02077868) is an open-label
Phase III trial with participation of AIO, TTD, and
GERCOR cooperative groups, designed to confirm the
encouraging evidence from IMPACT. mCRC patients
having achieved an objective tumor response following
first line induction therapy with or without biological
agents are randomized to receive MGN1703 switch main-
tenance monotherapy in the experimental arm or local
standard of care in the control arm. In case of relapse,
patients will reintroduce the initial induction treatment
whenever feasible, with those in the experimental arm
continuing to receive MGN1703 therapy. The primary
endpoint of the study will be OS. Secondary endpoints
include PFS, response rates, safety, and QoL in selected
centers. Type of induction treatment, CEA and activated
NKT at baseline are stratification factors for the study and
will be prospectively assessed. All randomized patients
take part in a comprehensive immune monitoring plan
evaluating cytokines and chemokines in serum and the
activation status of various immune cell populations.
Recruitment started in September 2014 and the study is
expected to recruit 540 patients within 24 months in 8
European countries.
After more than 100 patients have been recruited, first
exploratory immune monitoring data of patient’s blood
samples confirmed the MoA of MGN1703: A strong
activation was observed in monocytes (CD169+), a lesser
one in NK cells (CD69+), a moderate activation in NKT
cells and T cells (both CD69+). This immune profile is in
keeping with data obtained from the previous IMPACT
study.
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